Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
AbbVie Inc. v. Novartis Vaccines and Diagnostics, Inc. et al
Case Number:
3:17-cv-01815
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 31, 2017
Unclear Grammar Lands AbbVie-Novartis IP Row In Arbitration
A California federal judge on Thursday sent AbbVie Inc.'s suit seeking to nix Novartis' hepatitis C patents to arbitration, finding that while a licensing agreement between the companies was so grammatically unclear he consulted his Chicago Manual of Style, the ambiguity triggers a presumption in favor of the Federal Arbitration Act.
-
August 17, 2017
Grammar May Send AbbVie-Novartis IP Row To Arbitration
A California federal judge said Thursday he was likely to send AbbVie Inc.'s suit seeking to nix Novartis' hepatitis C patents to arbitration, saying a licensing agreement between the companies was grammatically vague about where invalidity arguments should be decided, and so he would follow a "general rule" of favoring arbitration.
-
April 03, 2017
Novartis' Hep C Patents Invalid Under Alice, AbbVie Says
AbbVie Inc. is looking to invalidate a suite of Novartis patents, arguing Friday in California that its Swiss rival is collecting licensing fees on the genetic makeup of the Hepatitis C virus, despite the U.S. Supreme Court's Alice ruling expressly stating nature itself can't be patented.